Soufflé Therapeutics™ Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline Progress
BOSTON, MA, OCTOBER 13, 2026 — SOUFFLÉ THERAPEUTICS, INC. (“Souffle™” or “Company”), a leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives, today announced the close of an oversubscribed $135...
